MoonLake Immunotherapeutics faces class action
Analysis based on 8 articles · First reported Oct 30, 2025 · Last updated Dec 03, 2025
The market is impacted by the potential financial liabilities and reputational damage to Alladapt Immunotherapeutics, which could lead to a decrease in its stock price. Investors who purchased shares during the class period may seek recovery for their losses.
The Gross Law Firm has issued multiple notices to shareholders of Alladapt Immunotherapeutics regarding a securities class action lawsuit. The lawsuit alleges that Alladapt Immunotherapeutics made materially false and/or misleading statements and failed to disclose crucial information about its sole drug candidate, SLK. Specifically, the complaint claims that SLK and BIMZELX share the same molecular targets, and SLK's distinct Nanobody structure would not offer superior clinical benefits or increased tissue penetration translating to clinical efficacy over BIMZELX. These alleged misrepresentations led to an artificial inflation of Alladapt Immunotherapeutics' stock price. Shareholders who purchased shares between March 10, 2024, and September 29, 2025, are encouraged to contact The Gross Law Firm to potentially be appointed as lead plaintiff, with a deadline of December 15, 2025.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard